IT Systems Manager
Celea Therapeutics
IT Systems Manager
Celea Therapeutics
Clinical-stage biopharma developing deupirfenidone for IPF
About Celea Therapeutics
Celea Therapeutics is dedicated to advancing transformative treatments for people with serious respiratory diseases. Drawn from the Latin word for “sky,” our name reflects our mission to rise above the status quo and deliver therapies that change lives. Our lead program, deupirfenidone (LYT-100), is currently in Phase 3 clinical development with active candidate enrollment, representing a potential new standard of care for idiopathic pulmonary fibrosis (IPF) and other fibrotic lung diseases.
Rising above the status quo takes a team as strong as its science, and we hire and work by five values: accountability — owning outcomes and acting like owners; transparency — talking straight and building trust; collaboration — achieving together what no one could alone; innovation — challenging accepted ideas and taking smart risks; and passion — bringing energy and heart to the mission.
We are seeking a skilled and customer-focused IT Systems Manager, AI Administration to support and maintain our Microsoft 365 environment, end-user computing infrastructure, and corporate technology services. This role administers Microsoft 365 services, provisions and deploys laptops, manages user accounts and permissions, troubleshoots technical issues, and supports conference room technology across the organization.
The ideal candidate is a Microsoft-certified IT professional with strong technical knowledge, excellent customer service skills, and the ability to work effectively in a fast-paced environment.
Reports to: Vice President, Information Technology | Location: Boston, MA (hybrid) | Employment Type: Full-time
Key Responsibilities
Microsoft 365 Administration
Endpoint Management & Laptop Deployment
User Administration
Technical Support & Help Desk
AI Innovation & Automation
Conference Room & Collaboration Technology Support
Security & Compliance
Required Qualifications
Technical Skills
Soft Skills
Preferred Qualifications
Success Factors
The successful candidate will be proactive, customer-focused, technically strong, and committed to improving the end-user technology experience while maintaining a secure and reliable IT environment.
Why Join Celea Therapeutics
Compensation
Transparency is one of our values, and that includes how we pay. The anticipated salary range for this role is $125,000 to $155,000, plus bonus and equity. Where an offer lands within the range reflects the candidate’s experience, skills, and internal equity — and we welcome open conversations about compensation from the first call, so there are no surprises at the offer stage.
Actual compensation will be determined based on experience, qualifications, and location. In addition to base pay, this role is eligible for bonus and equity compensation.
Our Commitment
Celea Therapeutics is an equal opportunity employer. We evaluate every candidate against the requirements of the role using a structured, evidence-based process, and we make employment decisions without regard to race, color, religion, sex, sexual orientation, gender identity, national origin, age, disability, veteran status, or any other legally protected characteristic.
For more information, visit www.celeatx.com or connect with us on Twitter @celeatx.
Base Pay Information 125000 - 155000 USD
Clinical-stage biopharma developing deupirfenidone for IPF
Celea Therapeutics develops and advances treatments for severe respiratory diseases, focusing on late-stage development of deupirfenidone (LYT-100), a deuterated form of pirfenidone. Its lead program targets idiopathic pulmonary fibrosis (IPF) and other fibrotic lung diseases and is prepared for Phase 3 trials. Deupirfenidone aims to slow lung function decline and improve tolerability by changing how the drug is processed in the body, potentially offering advantages over current IPF therapies. The company pursues a Phase 3 head-to-head trial (SURPASS-IPF) against an approved therapy, supported by Orphan Drug Designations and funding from investors, with PureTech Health retaining a meaningful stake.
Explore more opportunities at Celea Therapeutics